ISG Expression-Based ARDS Stratification and Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The variability in severity and treatment outcomes for Acute Respiratory Distress Syndrome (ARDS) is not fully understood, and current methods lack effective strategies for personalized treatment based on interferon-stimulated genes (ISG) expression levels.
Innovation Solution
A method involving the determination of ISG expression levels in subjects using quantitative PCR to identify severe ARDS cases, with treatment strategies involving ISG suppressing agents for elevated expression and enhancing agents for decreased expression, allowing for personalized therapeutic approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current standardized treatment methods are used for ARDS, then treatment can be applied universally, but treatment outcomes vary significantly due to unaddressed individual variability in ISG expression
Solution Approach 1:
The patent applies local quality by determining ISG expression levels in specific patient samples and tailoring treatment to individual expression profiles. Treatment is customized based on local characteristics (ISG expression levels) rather than applying uniform treatment to all patients, thereby improving outcome consistency while enabling personalized therapy.
Solution Approach 2:
The patent utilizes parameter changes by measuring ISG expression levels as a biomarker to stratify patients into different risk categories. Treatment decisions are based on changes in expression levels of specific genes (e.g., ISG15, IFIT1, MX1), allowing clinicians to adjust therapy intensity and type according to the measured parameter values.
2Adaptability or versatility
If ISG expression levels are determined for all ARDS patients, then personalized treatment can be implemented, but diagnostic complexity and time increase
Solution Approach 1:
The patent segments the complex diagnostic process into focused measurement of specific ISG expression levels (such as ISG15, IFIT1, MX1) rather than comprehensive genomic analysis. This segmentation reduces diagnostic complexity while maintaining the ability to provide personalized treatment based on clinically relevant biomarkers.
Solution Approach 2:
The patent uses ISG expression levels as intermediary biomarkers that mediate between complex molecular pathways and clinical treatment decisions. These intermediaries simplify the diagnostic process by providing measurable indicators that correlate with disease severity and treatment response, avoiding the need for direct intervention in complex biological systems.
3Adaptability or versatility
If ISG expression levels are determined for all ARDS patients, then personalized treatment can be implemented, but time to initiate treatment may be delayed
Solution Approach 1:
The patent enables preliminary action by establishing ISG expression level thresholds and treatment protocols in advance. Clinicians can quickly reference pre-determined expression level ranges (e.g., high, intermediate, low ISG15 expression) and corresponding treatment recommendations, allowing rapid decision-making without time-consuming analysis during acute patient presentation.
Data Source
AI summary
The present invention is related to novel methods for categorizing and treating subjects having Acute Respiratory Distress Syndrome (ARDS).